Why the study?
Does H-FABP measurement improve early diagnosis and prognosis in patients presenting with suspected ACS compared to conventional biomarkers?
Does H-FABP measurement improve early diagnosis and prognosis in patients presenting with suspected ACS compared to conventional biomarkers?
H-FABP serves as a highly sensitive early diagnostic and prognostic biomarker for patients with suspected ACS, especially within 6 hours of symptom onset.
Answers are grounded in this paper and cite their sources.
H-FABP may aid early ACS triage in suspected cases; extends biomarker comparisons but leaves open prospective validation before practice change.
Although heart-type fatty acid-binding protein (H-FABP) can be a marker of sarcolemmal injury due to acute myocardial ischemia, the diagnostic or prognostic value is not established in patients with acute chest pain. This multicenter prospective study aimed to determine the diagnostic and prognostic values of H-FABP in 133 patients presenting to an emergency room with suspected acute coronary syndrome (ACS) by comparing with those of conventional biomarkers. H-FABP and myoglobin had greater positive results than did creatine kinase-MB or troponin T. Receiver operating characteristics analysis revealed that H-FABP was the most reliable for detection of ACS and that H-FABP had the greatest sensitivities for identification of patients requiring emergency hospitalization, coronary angiography, and interventional therapy within 7 days among the biomarkers. Thus, H-FABP can be an early diagnostic and prognostic biochemical marker, particularly within the first 6 h from the onset of chest symptoms, in patients with chest pain at an emergency department.
No takes yet. Share an insight, caveat, or question.
Nakata et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: